Literature DB >> 28597951

Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis.

Rodrigo Liberal1,2, Charlotte R Grant1, Muhammed Yuksel1, Jonathon Graham1, Alireza Kalbasi3, Yun Ma1, Michael A Heneghan1, Giorgina Mieli-Vergani1,4, Diego Vergani1, Maria Serena Longhi1,3.   

Abstract

Imbalance between T regulatory (Treg) and T effector (Teff) cells is likely to contribute to the induction and perpetuation of liver damage in autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability of Tregs to restrain proliferation and effector cytokine production by responders or through conversion of Tregs into T helper type 1 (Th1) or type 17 (Th17) effector lymphocytes. We investigated the effect of Treg skewing on the phenotypic and functional properties of CD4+ CD127+ CD25high cells, an activated subset of Teff, in 32 patients with AIH and 20 with AISC and in 36 healthy subjects. In AIH/AISC we noted a substantial increase in peripheral blood-derived CD4+ CD127+ CD25high cells that display a Th1/Th17 phenotypic profile, as reflected by heightened interferon gamma and interleukin 17 (IL-17) production as well as by high levels of T-bet and related orphan receptor 3 expression, which is strongly correlated with disease activity. CD4+ CD127+ CD25high cells are unresponsive to low-dose IL-2 and in patients have marked proliferative ability, further enhanced by stimulation with IL-7. CD4+ CD127+ CD25high cells obtained from CD4+ cells exposed to Treg polarizing conditions display enhanced IL-10 production; up-regulate CD49b and LAG-3, markers of T regulatory 1 cells; and effectively suppress responder cell proliferation in both healthy subjects and AIH/AISC patients through a mechanism which is dependent on interferon gamma and IL-17. The suppressive function of CD4+ CD127+ CD25high cells is maintained upon proinflammatory challenge in healthy subjects but not in AIH/AISC.
CONCLUSION: Treg skewing confers activated Teff phenotypic and functional properties of T regulatory 1 cells in health and in AIH/AISC, though suppressive function is lost in patients upon proinflammatory challenge; protracted modulation of the inflammatory environment is required to attenuate the effector potential while boosting immunoregulatory properties in Teff. (Hepatology 2017;66:1570-1584).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28597951      PMCID: PMC5689077          DOI: 10.1002/hep.29307

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

1.  Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis.

Authors:  Maria Serena Longhi; Munther J Hussain; Ragai R Mitry; Sunil K Arora; Giorgina Mieli-Vergani; Diego Vergani; Yun Ma
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

2.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

3.  Interleukin-7 matures suppressive CD127(+) forkhead box P3 (FoxP3)(+) T cells into CD127(-) CD25(high) FoxP3(+) regulatory T cells.

Authors:  V Di Caro; A D'Anneo; B Phillips; C Engman; J Harnaha; R Lakomy; A Styche; M Trucco; N Giannoukakis
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

4.  Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis.

Authors:  Yin-Hu Wang; Wei Yang; Jing-Bo Yang; Yan-Jie Jia; Wei Tang; M Eric Gershwin; William M Ridgway; Zhe-Xiong Lian
Journal:  J Autoimmun       Date:  2015-02-17       Impact factor: 7.094

5.  Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.

Authors:  Maria Serena Longhi; Yun Ma; Dimitrios P Bogdanos; Paul Cheeseman; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Hepatol       Date:  2004-07       Impact factor: 25.083

6.  Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis.

Authors:  Ruth Y Lan; Chunmei Cheng; Zhe-Xiong Lian; Koichi Tsuneyama; Guo-Xiang Yang; Yuki Moritoki; Ya-Hui Chuang; Takafumi Nakamura; Shigeru Saito; Shinji Shimoda; Atsushi Tanaka; Christopher L Bowlus; Yasuo Takano; Aftab A Ansari; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

7.  Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis.

Authors:  Weici Zhang; Rahul Sharma; Shyr-Te Ju; Xiao-Song He; Yanyan Tao; Koichi Tsuneyama; Zhigang Tian; Zhe-Xiong Lian; Shu Man Fu; M Eric Gershwin
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

8.  Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis.

Authors:  C R Grant; B S Holder; R Liberal; M A Heneghan; Y Ma; G Mieli-Vergani; D Vergani; M S Longhi
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

9.  Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression.

Authors:  Li Zhao; Yanli Tang; Zhengrui You; Qixia Wang; Shuwen Liang; Xiaofeng Han; Dekai Qiu; Jue Wei; Yuan Liu; Lei Shen; Xiaoyu Chen; Yanshen Peng; Zhiping Li; Xiong Ma
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

10.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more
  18 in total

1.  Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease.

Authors:  René J Robles; Samiran Mukherjee; Marta Vuerich; Anyan Xie; Rasika Harshe; Peter J Cowan; Eva Csizmadia; Yan Wu; Alan C Moss; Ridong Chen; Simon C Robson; Maria Serena Longhi
Journal:  J Crohns Colitis       Date:  2020-07-09       Impact factor: 9.071

2.  Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis.

Authors:  Jonathon J Graham; Sujit Mukherjee; Muhammad Yuksel; Rebeca Sanabria Mateos; Tengfei Si; Zhenlin Huang; Xiahong Huang; Hadil Abu Arqoub; Vishal Patel; Mark McPhail; Yoh Zen; Nigel Heaton; Maria Serena Longhi; Michael A Heneghan; Rodrigo Liberal; Diego Vergani; Giorgina Mieli-Vergani; Yun Ma; Bu'Hussain Hayee
Journal:  Hepatology       Date:  2021-12-07       Impact factor: 17.425

3.  Activation of AMPKα1 is essential for regulatory T cell function and autoimmune liver disease prevention.

Authors:  Huaiping Zhu; Zhaoyu Liu; Junqing An; Miao Zhang; Yu Qiu; Ming-Hui Zou
Journal:  Cell Mol Immunol       Date:  2021-11-02       Impact factor: 11.530

4.  Immune Alterations in Patients With Type 1 Autoimmune Hepatitis Persist Upon Standard Immunosuppressive Treatment.

Authors:  Amédée Renand; Sarah Habes; Jean-François Mosnier; Hélène Aublé; Jean-Paul Judor; Nicolas Vince; Philippe Hulin; Steven Nedellec; Sylvie Métairie; Isabelle Archambeaud; Sophie Brouard; Jérôme Gournay; Sophie Conchon
Journal:  Hepatol Commun       Date:  2018-08-06

5.  Foxp3⁺ Treg Cells Are Associated with Pathological Process of Autoimmune Hepatitis by Activating Methylation Modification in Autoimmune Hepatitis Patients.

Authors:  Jiang Chen; Wen Liu; Wenjing Zhu
Journal:  Med Sci Monit       Date:  2019-08-18

6.  Diammonium Glycyrrhizinate Mitigates Liver Injury Via Inhibiting Proliferation Of NKT Cells And Promoting Proliferation Of Tregs.

Authors:  Meixin Gao; Xiulan Li; Lingling He; Junru Yang; Xiaohui Ye; Fan Xiao; Hongshan Wei
Journal:  Drug Des Devel Ther       Date:  2019-10-16       Impact factor: 4.162

7.  Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group.

Authors:  Nwe Ni Than; James Hodson; Daniel Schmidt-Martin; Richard Taubert; Rebecca E Wawman; Meemee Botter; Nishant Gautam; Kilian Bock; Rebecca Jones; Gautham D Appanna; Andrew Godkin; Aldo J Montano-Loza; Frank Lammert; Christoph Schramm; Michael P Manns; Mark Swain; Kelly W Burak; David H Adams; Gideon M Hirschfield; Ye Htun Oo
Journal:  JHEP Rep       Date:  2019-11-05

Review 8.  Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects.

Authors:  Hong Lei; Petra Reinke; Hans-Dieter Volk; Yi Lv; Rongqian Wu
Journal:  Front Immunol       Date:  2019-11-19       Impact factor: 7.561

9.  The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.

Authors:  Han Wang; Xinxia Feng; Ping Han; Yu Lei; Yujia Xia; Dean Tian; Wei Yan
Journal:  Mol Med Rep       Date:  2019-10-16       Impact factor: 2.952

Review 10.  Immunopathobiology and therapeutic targets related to cytokines in liver diseases.

Authors:  Yong He; Seonghwan Hwang; Yeni Ait Ahmed; Dechun Feng; Na Li; Marcelle Ribeiro; Fouad Lafdil; Tatiana Kisseleva; Gyongyi Szabo; Bin Gao
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.